Rosenblatt has maintained a positive stance on Pegasystems (NASDAQ: NASDAQ:), reiterating a Buy rating and a price target of $90.00. The firm’s outlook is based on expectations for the company’s third-quarter results for the period ending September 30th, anticipated to be released around October 23rd, after the market closes. Rosenblatt has made slight revisions to its forecasts for Pegasystems for the fiscal years 2024 and 2025. The firm cites a relatively stable process automation application spending environment in North America, which accounts for approximately 55% of Pegasystems’ revenue. The analyst points to ongoing Digital Transformation programs among Pegasystems’ existing customers,…
Author: user
US stock futures climbed before the bell on Tuesday as investors welcomed a pullback in surging oil prices, putting focus back on the ongoing debate over the economy and interest rates.Futures on the S&P 500 (ES=F) stepped up 0.4%, while Nasdaq 100 (NQ=F) rose 0.5% as tech megacaps began to recoup some of the previous session’s losses. Dow Jones Industrial Average futures (YM=F) edged up roughly 0.2%.Stocks are set to pick up on the winning trend of recent months as Monday’s headwinds ease. Oil prices are retreating as Mideast tensions cool somewhat, while the 10-year Treasury yield (^TNX) briefly slipped…
Image source: Getty Images Here’s a dirt cheap FTSE 250 share and a top exchange-traded fund (or ETF) on my shopping list this October. AI frenzy The market buzz around artificial intelligence (AI) remains intense. So as concerns over Nvidia‘s high valuation remain, share pickers are buying other, more reasonably-priced companies to capitalise on this new tech frontier. During Q3, semiconductor and chip manufacturers dominated the list of companies with the largest proportionate increase in UK retail investors. These companies accounted for five of the 10 biggest risers among eToro customers: StockIncrease in holders Q-o-QBroadcom25%ASML17%Super Micro Computer17%Intel17%Micron Technology15% eToro analyst…
BMO Capital Markets has adjusted its outlook on Canadian Natural (NYSE:) Resources Limited (CNQ: CN) (NYSE: CNQ), increasing its price target to C$60.00 from the previous C$57.50. The firm has retained its Outperform rating on the stock. The adjustment follows Canadian Natural’s announcement of the acquisition of Chevron (NYSE:)’s remaining interests in the Western Canadian Sedimentary Basin (WCSB). The analyst from BMO Capital highlighted that Canadian Natural is the natural buyer for Chevron’s stake in the Athabasca Oil (OTC:) Sands Project (AOSP) and secured the deal at an appealing price. Additionally, the acquisition includes the Duvernay asset, which is considered…
Image source: Getty Images The artificial intelligence (AI) revolution seems to have passed the Vodafone Group (LSE: VOD) share price by. In the US, AI-related stocks like Nvidia and Alphabet are soaring. But Vodafone shares have fallen more than 50% in the past five years. I think that could change, and it’s all to do with Alphabet, the Google holding company. Billion dollar+ On Wednesday (8 October), Vodafone announced a 10-year extension to its strategic partnership with Google. As part of the new deal, said to be worth more than $1bn, “Vodafone will expand access to Google’s AI-powered Pixel devices…
NOAA GOES East satellite image of Hurricane Milton on Oct. 8th, 2024.NOAA GOES EastHurricane Milton weakened slightly Tuesday but remained a ferocious storm that could land a once-in-a-century direct hit on Tampa and St. Petersburg, engulfing the populous region with towering storm surges and turning debris from Helene’s devastation 12 days ago into projectiles.Almost the entirety of Florida’s west coast was under a hurricane warning as the storm and its 155 mph (250 kph) winds spun just off Mexico’s Yucatan peninsula, creeping toward the state at 12 mph (19 kph) and sucking energy from the Gulf of Mexico’s warm waters.Milton’s…
Cantor Fitzgerald began coverage on shares of Bicara Therapeutics Inc (NASDAQ:BCAX), assigning an Overweight rating to the biopharmaceutical company. The firm highlighted the potential of Bicara’s leading drug candidate, ficerafusp alfa, which is being developed as a treatment for head and neck squamous cell carcinoma (HNSCC). Bicara Therapeutics is at the forefront with ficerafusp alfa, a bifunctional antibody targeting EGFR and TGF-β. The drug is progressing towards a Phase 3 trial for first-line HNSCC, bolstered by promising Phase 2 data. The analyst at Cantor Fitzgerald expressed optimism about the drug’s prospects, suggesting that it could establish itself as a standard-of-care…
These are the upcoming stock splits for the week of October 7 to October 11, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split.In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate). In this case, too, the market cap is maintained as the share price increases following the reverse stock split.Companies often undertake stock splits to…
Image source: Getty Images The Imperial Brands (LSE: IMB) share price was posting a very healthy gain this morning (8 October) after publishing an update on trading to coincide with the end of its financial year. Let’s see what’s got investors cheering from the stands. Holding steady Perhaps most importantly, the company said it had been trading “in line with expectations“. That’s reassuring given the pressures many consumer defensive stocks have faced over the last year or so. Investment in its five priority markets also seems to have helped Imperial to maintain its market share with gains in Spain, Australia…
BOSTON – Amwell (NYSE: AMWL), a digital care company, has partnered with Hello Heart, a preventive heart health firm, to offer cardiovascular care solutions to health plan clients. This collaboration, announced today, integrates Hello Heart’s digital program into Amwell’s Converge platform, enabling members with heart disease risk factors like high blood pressure and high cholesterol to manage their conditions more effectively. The United States faces a significant burden from heart disease, the leading cause of death, with treatment costs averaging $12,500 per member annually for health plans. Nearly half of all U.S. adults suffer from high blood pressure, a major…